12 Health Care Stocks Moving In Monday's After-Market Session
Portfolio Pulse from Benzinga Insights
The article reports on the performance of health care stocks in Monday's after-market session, highlighting significant gainers and losers. Notably, Aesthetic Medical Intl, Harrow, and Vaxart experienced upward movements, attributed to recent earnings releases for some. Conversely, Augmedix, Akoya Biosciences, and Calidi Biotherapeutics saw notable declines, also influenced by their earnings reports.
May 13, 2024 | 8:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aesthetic Medical Intl's stock rose by 23.3% after the market, with a market value of $27.0 million, potentially due to positive investor sentiment.
The significant rise in AIH's stock price could be attributed to investor optimism, possibly due to internal developments or market conditions.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 90
POSITIVE IMPACT
Harrow's shares increased by 13.5% to $13.7, with a market value of $484.7 million, following the release of Q1 earnings.
The positive movement in Harrow's stock price post-Q1 earnings suggests favorable investor response to the financial results.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 95
POSITIVE IMPACT
Vaxart's stock increased by 12.19% to $0.92, with a market value of $162.6 million, following its Q1 earnings announcement.
Vaxart's stock appreciation post-Q1 earnings reflects investor optimism towards the company's financial health.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 95
NEGATIVE IMPACT
Akoya Biosciences' stock decreased by 19.91% to $3.3, with a market value of $162.9 million, following its Q1 earnings announcement.
The significant drop in Akoya Biosciences' stock price post-Q1 earnings reflects adverse investor reaction to the financial results.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 95
NEGATIVE IMPACT
Augmedix's shares fell by 33.8% to $1.55, with a market cap of $75.8 million, after its Q1 earnings were released.
The sharp decline in Augmedix's stock price post-Q1 earnings suggests negative investor sentiment towards the earnings report.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 95
NEGATIVE IMPACT
Calidi Biotherapeutics' shares fell 5.0% to $0.21, with a market value of $10.3 million, indicating a negative market reaction.
The decrease in Calidi Biotherapeutics' stock price may reflect investor concerns or dissatisfaction with the company's direction.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 80